Millie Garg1, Steven T Leach1, Michael J Coffey1, Tamarah Katz2, Roxanne Strachan3, Tamara Pang1, Bronwen Needham4, Kei Lui5, Fathalla Ali1, Andrew S Day6, Laura Appleton6, Vesal Moeeni6, Adam Jaffe7, Chee Y Ooi8. 1. School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia. 2. Department of Nutrition and Dietetics, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. 3. Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. 4. Sydney Medical Program, The University of Sydney, Camperdown 2050, New South Wales, Australia. 5. School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Newborn Care, The Royal Hospital for Women, Barker Street, Randwick 2031, New South Wales, Australia. 6. Department of Pediatrics, University of Otago, 2 Riccarton Ave, Christchurch 8011, Canterbury, New Zealand. 7. School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. 8. School of Women's and Children's Health, Medicine, The University of New South Wales, Sydney, New South Wales, Australia; Department of Gastroenterology, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. Electronic address: keith.ooi@unsw.edu.au.
Abstract
BACKGROUND: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). METHOD: Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends. RESULTS: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10years (P=0.0002). Fecal calprotectin in CF was significantly lower than HC from 0 to 1years (P=0.03) and demonstrated an upward trajectory until 4years. From >4 to 10years calprotectin was consistently higher in CF patients compared with HC (P=0.007). CONCLUSIONS: Fecal calprotectin levels in children with CF and HC were age-dependent and had distinct trajectories. Careful interpretation of calprotectin is required if used in drug trials for CF, particularly in children less than 4years old.
BACKGROUND: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). METHOD: Stools from CFpatients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends. RESULTS: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CFpatients and HC from 0 to 10years (P=0.0002). Fecal calprotectin in CF was significantly lower than HC from 0 to 1years (P=0.03) and demonstrated an upward trajectory until 4years. From >4 to 10years calprotectin was consistently higher in CFpatients compared with HC (P=0.007). CONCLUSIONS: Fecal calprotectin levels in children with CF and HC were age-dependent and had distinct trajectories. Careful interpretation of calprotectin is required if used in drug trials for CF, particularly in children less than 4years old.
Authors: Romy M Heilmann; Melissa M Guard; Linda Toresson; Stefan Unterer; Aurélien Grellet; Niels Grützner; Jan S Suchodolski; Joerg M Steiner Journal: Vet Med Sci Date: 2021-03-10
Authors: Meghana Sathe; Rong Huang; Sonya Heltshe; Alexander Eng; Elhanan Borenstein; Samuel I Miller; Lucas Hoffman; Daniel Gelfond; Daniel H Leung; Drucy Borowitz; Bonnie Ramsey; A Jay Freeman Journal: J Pediatr Gastroenterol Nutr Date: 2021-09-01 Impact factor: 3.288
Authors: Michael J Coffey; Ivan Low; Sacha Stelzer-Braid; Bernd Wemheuer; Millie Garg; Torsten Thomas; Adam Jaffe; William D Rawlinson; Chee Y Ooi Journal: PLoS One Date: 2020-05-22 Impact factor: 3.240
Authors: Adam T Fox; Harm Wopereis; Marleen T J Van Ampting; Manon M Oude Nijhuis; Assad M Butt; Diego G Peroni; Yvan Vandenplas; David C A Candy; Neil Shah; Christina E West; Johan Garssen; Lucien F Harthoorn; Jan Knol; Louise J Michaelis Journal: Clin Transl Allergy Date: 2019-01-15 Impact factor: 5.871
Authors: Molly Bozic; Christopher H Goss; Rabindra M Tirouvanziam; Arthur Baines; Margaret Kloster; Liebe Antoine; Drucy Borowitz; Sarah Jane Schwarzenberg Journal: J Pediatr Gastroenterol Nutr Date: 2020-12 Impact factor: 3.288